Renal denervation as option for patients with hypertension despite medications - PACE-CME

Renal denervation as option for patients with hypertension despite medications

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Can targeting of IL-6 lead to CV protection in CKD?
Can targeting of IL-6 lead to CV protection in CKD?
ACC.21
Can targeting of IL-6 lead to CV protection in CKD?
- Paul Ridker, MD
No superiority with NOAC compared to standard care following TAVI
No superiority with NOAC compared to standard care following TAVI
ACC.21
No superiority with NOAC compared to standard care following TAVI
- Jean-Philippe Collet, MD, PhD
No difference in clinical outcomes with 81 mg vs. 325 mg aspirin in established CVD
No difference in clinical outcomes with 81 mg vs. 325 mg aspirin in established CVD
ACC.21
No difference in clinical outcomes with 81 mg vs. 325 mg aspirin in established CVD
- William Schuyler Jones, MD
No definite difference for primary endpoint but proven safety with ARNI in MI patients
No definite difference for primary endpoint but proven safety with ARNI in MI patients
ACC.21
No definite difference for primary endpoint but proven safety with ARNI in MI patients
- Prof. Marc Pfeffer, MD, PhD